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Background. A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the majority of
patients with polycythemia vera (PV), and some with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis.
However, the role of mutant JAK2 in disease pathogenesis is unclear. Methods and Findings. We expressed murine JAK2 WT
or V617F via retroviral bone marrow transduction/transplantation in the hematopoietic system of two different inbred mouse
strains, Balb/c and C57Bl/6 (B6). In both strains, JAK2 V617F, but not JAK2 WT, induced non-fatal polycythemia characterized by
increased hematocrit and hemoglobin, reticulocytosis, splenomegaly, low plasma erythropoietin (Epo), and Epo-independent
erythroid colonies. JAK2 V617F also induced leukocytosis and neutrophilia that was much more prominent in Balb/c mice than
in B6. Platelet counts were not affected in either strain despite expression of JAK2 V617F in megakaryocytes and markedly
prolonged tail bleeding times. The polycythemia tended to resolve after several months, coincident with increased spleen and
marrow fibrosis, but was resurrected by transplantation to secondary recipients. Using donor mice with mutations in Lyn, Hck,
and Fgr, we demonstrated that the polycythemia was independent of Src kinases. Polycythemia and reticulocytosis responded
to treatment with imatinib or a JAK2 inhibitor, but were unresponsive to the Src inhibitor dasatinib. Conclusions. These
findings demonstrate that JAK2 V617F induces Epo-independent expansion of the erythroid lineage in vivo. The fact that the
central erythroid features of PV are recapitulated by expression of JAK2 V617F argues that it is the primary and direct cause of
human PV. The lack of thrombocytosis suggests that additional events may be required for JAK2 V617F to cause ET, but
qualitative platelet abnormalities induced by JAK2 V617F may contribute to the hemostatic complications of PV. Despite the
role of Src kinases in Epo signaling, our studies predict that Src inhibitors will be ineffective for therapy of PV. However, we
provide proof-of-principle that a JAK2 inhibitor should have therapeutic effects on the polycythemia, and perhaps
myelofibrosis and hemostatic abnormalities, suffered by MPD patients carrying the JAK2 V617F mutation.
Citation: Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, et al (2006) Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by
JAK2 V617F. PLoS ONE 1(1): e18. doi:10.1371/journal.pone.0000018
INTRODUCTION
The myeloproliferative diseases (MPDs) chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia (ET),
and chronic idiopathic myelofibrosis (CIMF) are clonal disorders
characterized by overproduction of mature myeloerythroid cells,
abnormalities of hemostasis and thrombosis, and tendency to
progress to acute leukemia [1,2]. The cause of CML is the product
of the Philadelphia chromosome, the BCR-ABL fusion tyrosine
kinase. Retroviral expression of BCR-ABL in murine bone
marrow (BM) causes CML-like MPD with overproduction of
maturing neutrophils [3], whereas the BCR-ABL kinase inhibitor
imatinib induces hematologic and cytogenetic remissions in CML
patients [4].
By contrast, the pathogenesis of the other MPDs is less clear. PV
is characterized by overproduction of mature erythrocytes,
increased hematocrit and red cell mass, and splenomegaly due
to extramedullary hematopoiesis [5]. Many PV patients also have
increased circulating granulocytes and platelets. PV can be
complicated by abnormalities of hemostasis, including platelet
dysfunction and bleeding, as well as arterial and venous
thrombosis. The disease infrequently evolves to acute myeloid
leukemia, while progression to a ‘‘spent’’ phase, characterized by
myelofibrosis and normal or low hematocrit, is more common. A
hallmark of PV is the presence of endogenous erythroid colonies
(EEC), erythroid progenitors that form colonies in vitro in the
absence of exogenous erythropoietin (Epo) [6], but demonstrate
hypersensitivity to insulin-like growth factor-1 [7]. Biochemical
and molecular studies of PV patients have revealed no mutations
in the Epo receptor, but granulocytes from PV patients have
increased transcripts for the urokinase plasminogen activator
receptor family member PRV-1 [8], whereas PV platelets show
decreased expression of c-Mpl, the receptor for thrombopoietin
[9]. Abnormally increased tyrosine phosphatase activity has also
been characterized in erythroid progenitors in PV [10]. However,
whether these abnormalities are fundamental to the pathogenesis
of PV was unclear.
JAK2 is a member of the Janus family of non-receptor tyrosine
kinases, and is required for signaling from the Epo receptor and
other type I cytokine receptors [11]. Recently, a somatic mutation
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Studies of erythroid progenitors from PV patients demonstrated
that Epo-independent erythroid maturation was impaired by
a JAK2 inhibitor [12] and by siRNA knockdown of JAK2 [13].
This prompted sequencing of the JAK2 gene, which identified a G
to A point mutation, resulting in substitution of phenylalanine for
valine at amino acid 617 (V617F) in the JAK2 pseudokinase
domain in the majority of PV patients [13]. The JAK2 V617F
mutant had constitutive kinase activity in vivo in the absence of
Epo stimulation, and retroviral expression in murine BM caused
erythrocytosis [13]. The same mutation was independently
identified through genomic sequencing of tyrosine kinases in
MPD patients [14,15], and by investigation of loss of heterozy-
gosity involving the JAK2 gene on chromosome 9p [16]. The
JAK2 V617F mutation is found in nearly every patient with PV
and is present in homozygous form through mitotic recombination
in up to 30% of patients. The mutation is also found in 30–60% of
ET and CIMF patients, but is rarely found outside MPD [17–19].
The widespread finding of JAK2 V617F in the non-CML
MPDs suggests that it may contribute to the pathogenesis of these
diseases. However, it is not clear whether JAK2 V617F can be
implicated as the direct and primary cause of PV, ET, or CIMF,
nor is the relationship between the different MPDs that share the
JAK2 mutation understood. Here, we investigated the role of
JAK2 V617F in the pathogenesis of MPD by expression of the
mutant kinase in the hematopoietic system of laboratory mice,
using retroviral BM transduction and transplantation. Our results
suggest that JAK2 V617F is the primary cause of PV, but not of
ET. We also used this model system to study the signaling
pathways in PV, and assess the response of the disease to kinase
inhibitor therapy.
METHODS
DNA constructs
The V617F mutation was generated in the murine JAK2 cDNA
using PCR mutagenesis, verified by DNA sequencing, and the
JAK2 WT or V617F mutant cDNAs cloned into the MIG R1
vector [20] in the position 59 to the internal ribosome entry site.
Retroviral BM transduction and transplantation
Generation and titering of replication-defective ecotropic retrovi-
ral stocks was done with the kat packaging system as previously
described [21]. Retroviral titers were matched by flow cytometric
analysis of GFP expression in transduced fibroblasts and primary
BM cells. We performed retroviral BM transduction and trans-
plantation as previously described [21], using donors pretreated
with 5-fluorouracil (200 mg/kg) four days before harvest, and
transplanting lethally irradiated recipients (900 cGy for Balb/c,
1050 cGy for B6). Balb/c and B6 mice were purchased from
Taconic Farms; Lyn
2/2Hck
2/2Fgr
2/2 mice (.15 generations
backcrossed into a B6 background) were the kind gift of Dr.
Clifford Lowell [22]. Diseased mice were analyzed by histopa-
thology and flow cytometric analysis as previously described [21].
Blood counts were determined by analysis of retro-orbital blood
samples, anticoagulated with potassium EDTA, on a Hemavet 850
rodent hematology analyzer (Drew Scientific).
Immunoblot analysis
Lysates were prepared from primary myeloerythroid cell suspen-
sions from BM and spleen by direct boiling, fractionated by SDS-
PAGE, and immunoblotted as previously described [21]. Anti-
bodies against JAK2, Bcl-XL, and Src were obtained from Upstate
Biotechnology, while antibodies against Gab2 were the kind gift of
Haihua Gu (Beth Israel-Deaconess Hospital, Boston). All other
antibodies, including anti-phospho-Tyr1007/1008 JAK2, anti-
phospho-Tyr416 Src, anti-phospho and anti-pan Stat5, anti-
phospho-Gab2, and phospho- and anti-pan ERK were obtained
from Cell Signaling Technology.
Southern blot analysis
The number of proviral clones in BM and spleen cells from mice
with JAK2 V617F-induced MPD was determined by digesting
genomic DNA with BglII, fractionation on agarose gels, transfer to
nylon membranes, and hybridization with a radiolabeled probe
from the GFP gene, as described [21].
Analysis of erythrocyte lifespan and mass
Erythrocyte lifespan was determined by in vivo biotinylation of
erythrocytes and serial flow cytometric detection of biotinylated
red cells using streptavidin-PE, as described [23]. For red cell mass
determination, approximately 0.5 ml of peripheral blood was
obtained from a healthy donor mouse and biotinylated in vitro as
described [23]. The concentration of erythrocytes was determined
by counting on a Hemavet 850 hematology analyzer and the
percentage of biotinylated erythrocytes determined by FACS. A
defined volume (200–300 ml) was then injected into normal or
polycythemic recipient mice, whose peripheral blood was sampled
two hours later. The total RBC mass was calculated by the
following formula: total RBC mass=(%labeling of donor RBC/
100)6(#RBC/mL in donor sample)6(#mL injected)6100/(%la-
beled RBC in recipient).
CFU-E and Epo assays
BM or spleen cells were plated in methylcellulose (MethoCult
M3234, Stem Cell Technologies) with 5 ng/ml recombinant
murine IL-3 (Peprotech) as a source of burst-promoting activity
and varying concentrations of recombinant human Epo (Ortho).
CFU-E colonies were identified on day 3 by morphology and
diaminofluorine staining. Plasma Epo levels were determined by
ELISA (R&D Systems).
Tail bleeding time
Tail bleeding times were determined as previously described [24].
Briefly, following induction of isoflurane anesthesia, a 5 mm
portion of the tail tip was severed by scalpel and the tip immersed
in 0.9% saline solution at 37uC. The time of cessation of
spontaneous bleeding was recorded; if bleeding continued for
more than 15 minutes, the time was recorded as 900 seconds, and
hemostasis achieved by cauterization of the tail tip.
Purification of megakaryocytes
Megakaryocytes were purified after in vitro growth as previously
described [25]. Briefly, BM or spleen cells were grown for 72–
96 hours in IMDM with 1% Nutridoma (Roche) and 38 ng/ml
recombinant human thrombopoietin (Peprotech), and megakar-
yocytes purified by sedimentation over a discontinuous albumin
gradient. The resulting population was .95% megakaryocytes
based on morphology and staining for CD41 and acetylcholines-
terase.
Drug treatments
Imatinib (obtained from the pharmacy) and dasatinib (kind gift of
Drs. Frank Lee and Roberto Weinmann, Bristol-Myers Squibb)
were dissolved in a water:propylene glycol (50:50) vehicle and
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PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e18Figure 1. JAK2 V617F induces polycythemia through autonomous overproduction of erythrocytes. (A–C): Hematocrit (A), blood hemoglobin (B), and
reticulocyte counts (C) from cohorts of Balb/c or B6 mice transplanted with syngeneic BM cells transduced with empty vector (green, n=2), or
retrovirus expressing murine JAK2 WT (blue, n=10) or JAK2 V617F (red, n=15). In the case of the B6 cohorts, untransplanted mice (‘‘Normal’’, n=4)
were used instead of empty vector controls. The difference between JAK2 V617F and JAK2 WT recipients was significant (unpaired t-test) for
hematocrit (P,0.0001 for Balb/c and P=0.0071 for B6), hemoglobin (P=0.0011 for Balb/c and P=0.0024 for B6), and reticulocytes (P,0.0001 for
Balb/c and P=0.0195 for B6), while there were no significant differences between vector and JAK2 WT recipients. (D) Reticulocyte stains of peripheral
blood from recipients of BM transduced with JAK2 WT (left) or JAK2 V617F (right). (E–F): Erythrocyte survival curves (E) and red cell mass
determination (F) for the three groups (Balb/c background). The red cell mass of JAK2 V617F recipients was significantly greater than that of
recipients of vector- or JAK2 WT-transduced BM (P=0.0068 and P=0.0009, respectively, unpaired t-test). (G) Plasma Epo levels for the three groups
(B6 background). The mean Epo level (bar) of JAK2 V617F recipients was significantly lower than that of recipients of vector- or JAK2 WT-transduced
BM (P=0.0048 and P=0.0151, respectively, unpaired t-test). (H) Number of CFU-E colonies from normal BM (green) or spleen of JAK2 V617F recipients
(red), expressed as percent of maximal colony number (Balb/c background). Data for JAK2 WT recipients were similar to normal mice (data not
shown). All studies were carried out between 6 and 10 weeks post-transplantation.
doi:10.1371/journal.pone.0000018.g001
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10 mg/kg [27] per dose, respectively. Control mice received
vehicle alone. AG-490 (Calbiochem) was dissolved in 50% DMSO
and delivered by subcutaneous osmotic minipump (Alzet model
2002) at a rate of about 300 mg per 24 hours, while control mice
received minipumps loaded with 50% DMSO alone.
RESULTS
JAK2 V617F induces polycythemia through Epo-
independent overproduction of erythrocytes
To investigate the molecular pathogenesis of MPD induced by
JAK2 V617F, we expressed murine JAK2 WT or JAK2 V617F in
BM of two different strains of mice, Balb/c and C57Bl/6 (B6),
using retroviral transduction and transplantation [21]. In both
strains, recipients of JAK2 V617F-transduced BM exhibited
markedly increased blood hematocrit and hemoglobin levels that
were evident by three weeks after transplantation and sustained for
months (Figure 1A and 1B), while recipients of JAK2 WT- or
vector-transduced BM were normal. Polycythemia was accompa-
nied by a striking increase in circulating reticulocytes (Figure 1C
and 1D). The erythrocyte lifespan in JAK2 V617F recipients was
normal (Figure 1E), and polycythemia was accompanied by
a proportional increase in red cell mass (Figure 1F). These results
indicate that the polycythemia in these recipients was due to
primary overproduction of erythrocytes, not to an increase in red
cell survival or decrease in plasma volume. Plasma Epo levels were
suppressed in JAK2 V617F recipients (Figure 1G), demonstrating
that the erythropoiesis in these mice is autonomous, and not
driven by overproduction of Epo. CFU-E from BM or spleen of
these recipients showed increased sensitivity to Epo, with about
25–30% of CFU-E growing in the absence of exogenous Epo
(Figure 1H), demonstrating the presence of EEC in the poly-
cythemic mice. Interestingly, the frequency of Epo-independent
BFU-E in these recipients was much lower (data not shown),
suggesting that JAK2 V617F acts in the most differentiated
erythroid progenitors to promote Epo-independent maturation.
Together, these results indicate that JAK2 V617F expression
directly induces polycythemia in mice through Epo-independent
Figure 2. Effect of JAK2 V617F on leukocyte and platelet counts. (A) Peripheral blood leukocyte counts for the three cohorts in Balb/c and B6
backgrounds as in Figure 1. The difference in leukocyte counts between JAK2 V617F and JAK2 WT recipients was significant for the Balb/c cohort
(P=0.0039) but not for B6 (P=0.0542, unpaired t-test). The hatched portion of the histogram represents the percentage of the total leukocyte count
comprised by neutrophils. (B) Wright-Giemsa-stained cytospins of peripheral blood leukocytes from representative mice with BCR-ABL-induced CML-
like MPD (left) or JAK2 V617F-induced PV-like MPD (right). Note the predominance of mature neutrophils and lack of immature myeloid elements
(myelocytes and promyelocytes) in the JAK2 V617F recipient. (C) Platelet counts for the groups in (A). There was no significant difference in platelet
counts between the three cohorts in either stain. (D) GFP fluorescence (left panels) and phase contrast images (right panels) of purified
megakaryocytes from recipients of JAK2 V617F-transduced BM (top panels) or normal control mice (bottom panels). Note the GFP fluorescence in the
majority of megakaryocytes from JAK2 V617F recipients. (E) Tail bleeding time (Balb/c cohort) for the three groups. The mean bleeding time (bar) of
JAK2 V617F recipients was significantly longer than that of vector or JAK2 WT recipients (P=0.0328 and P=0.0002, respectively, unpaired t-test).
doi:10.1371/journal.pone.0000018.g002
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features of PV are recapitulated by expression of JAK2 V617F
argues that it is the primary and direct cause of human PV.
JAK2 V617F induces strain-dependent leukocytosis,
but not thrombocytosis
In contrast to the polycythemia, the effects of JAK2 V617F
expression on leukocyte and platelet counts were more variable.
JAK2 V617F induced significant leukocytosis in Balb/c mice, but
only a modest increase in B6 mice (Figure 2A). The majority of the
leukocytes were mature neutrophils with some immature erythroid
cells (Figure 2A and 2B), and there was a notable absence of
circulating immature myeloid progenitors that are characteristic of
BCR-ABL-induced CML-like MPD (Figure 2B). These results
suggest that genetic differences between the two mouse strains
affect the leukocytosis induced by JAK2 V617F. JAK2 V617F
expression did not affect the platelet count in either strain
(Figure 2C), despite evidence of proviral expression of GFP in
megakaryocytes (Figure 2D). However, JAK2 V617F recipients
had a marked defect in platelet function, with significantly
prolonged tail bleeding time (Figure 2E). The lack of thrombo-
cytosis suggests that additional events may be required for JAK2
V617F to cause ET, but qualitative platelet abnormalities induced
by JAK2 V617F may contribute to the hemostatic complications
of PV.
Figure 3. Histopathological characterization of the MPD induced by JAK2 V617F. (A–C): Hematoxylin and eosin stains (magnification 5006) of BM (A),
spleen (B), and liver (C) from representative polycythemic recipients of JAK2 V617F-transduced BM. In the spleen, a lymphoid follicle (f) and an area of
erythroid hyperplasia (e) are indicated. The same tissues from recipients of JAK2 WT-transduced BM showed no pathological changes compared with
normal controls (data not shown). (D) Wright-Giemsa stains (top panels) and acetylcholinesterase stains (bottom panels) of purified megakaryocytes
from recipients of JAK2 V617F-transduced BM (right panels) or normal control mice (left panels). Note the preponderance of small megakaryocytes
from JAK2 V617F recipients, some of which are undergoing proplatelet formation (arrowheads), accompanied by abnormal mitoses with low
apparent ploidy (insert). (E) Flow cytometric analysis of BM and spleen from a representative recipient of JAK2 V617F-transduced BM, stained with the
indicated hematopoietic lineage antigens. The mean fluorescence intensity of GFP expressed from JAK2 retroviral provirus was reproducibly and
significantly lower than the GFP fluorescence of a comparable BCR-ABL retrovirus (data not shown). Note the shift of GFP
+/lo erythropoiesis (TER-119
+)
from BM to spleen and the expression of GFP in low abundance CD41
+ megakaryocytes. (F) Flow cytometric assessment of erythrocyte differentiation
[47], assessed by expression of transferrin receptor (CD71) and TER-119 in splenocytes of recipients of JAK2 WT-transduced (top) and JAK2 V617F-
transduced (bottom) BM. Note the increased (3.5-fold) population of CD71
+/loTER-119
+ erythroblasts in JAK2 V617F recipients.
doi:10.1371/journal.pone.0000018.g003
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JAK2 V617F
Despite the marked polycythemia, the MPD induced by JAK2
V617F was non-fatal in both strains, with recipients surviving for
many months. By contrast, BCR-ABL-induced CML-like MPD is
rapidly fatal in mice due to massive infiltration of lungs, liver, and
spleen with maturing neutrophils [21]. At autopsy, JAK2 V617F
recipients had significant splenomegaly, particularly in Balb/c
mice (mean spleen weight 0.5860.19 g versus 0.0860.01 for
Balb/c recipients of JAK2 WT-transduced BM, P=0.0023 by
unpaired t-test), but no involvement of lymph nodes or thymus,
and no pulmonary hemorrhages. The BM of JAK2 V617F
recipients was hypercellular, with a predominance of myeloid over
erythroid cells, and less than 5% blasts (Figure 3A). Spleens
exhibited massively increased erythroid precursors with partial
disruption of follicular architecture and infiltration with mature
myeloid cells (Figure 3B). Livers showed moderate periportal
extramedullary myeloerythropoiesis (Figure 3C), while lungs had
only minimal myeloid infiltration (data not shown). There were
increased numbers of abnormal megakaryocytes present in BM
and spleen (Figure 3A and 3B). When isolated after in vitro culture
in thrombopoietin, megakaryocytes from JAK2 V617F recipients
were noticeably smaller than their counterparts from normal mice
or JAK2 WT recipients (Figure 3D), with many micromegakar-
yotes undergoing proplatelet formation and mitosis. Flow
cytometric analysis of BM and spleen (Figure 3E) demonstrated
GFP expression in myeloid, erythroid, megakaryocytic, and
lymphoid cells, with a shift in erythropoiesis to the spleen, and
a relative increase in immature (CD71
+/loTER119
+) erythroid
progenitors (Figure 3F).
Constitutive activation of JAK2 V617F and
downstream signaling pathways in polycythemic
mice
To determine the biochemical properties of JAK2 V617F in vivo,
we performed western blot analysis of extracts from primary
myeloerythroid cells from recipients of JAK2 V617F- and JAK2
WT-transduced BM. There was modest (2- to 3-fold) over-
expression of JAK2 in both cohorts, relative to the level of
endogenous JAK2 protein (Figure 4A). There was constitutive
activation of JAK2 V617F in BM and spleen cells, as evidenced by
phosphorylation at the activation loop tyrosines 1007 and 1008,
whereas JAK2 WT was not detectably phosphorylated. We also
analyzed several signaling pathways that are activated by Epo
receptor (Figure 4B). There was increased phosphorylation of
Gab2 and ERK in spleens and BM from JAK2 V617F recipients
that were somewhat variable from sample to sample, but no
consistent activation of Akt (data not shown). There was
constitutive activation of Stat5 and detectable expression of the
Stat5 target Bcl-XL in BM of both normal and polycythemic mice,
with increased Stat5 phosphorylation and Bcl-XL in spleens from
JAKV617F recipients, although this could in part reflect the
increase in splenic myeloerythroid cells in these mice. These results
suggest that JAK2 V617F activates several signaling pathways in
primary murine hematopoietic cells. Southern blot analysis of
proviral integration demonstrated that multiple proviral clones
contributed to the MPD induced by JAK2 V617F (Figure 4C),
similar to that observed for BCR-ABL-induced CML-like MPD
[21].
Progression of polycythemia to myelofibrosis
The polycythemia induced by JAK2 V617F was maximal at 3 to
4 months post-transplantation, but tended to decrease with time in
both strains, with hematocrit and reticulocyte counts returning to
nearly normal ranges by 7 to 8 months after transplantation
(Figure 5A), and some mice developing overt anemia. This
coincided with a gradual but marked increase in fibrosis in the BM
and spleen of JAK2 V617F recipients that was not observed in
JAK2 WT recipients (Figure 5B). This is reminiscent of evolution
of human PV to a ‘‘spent phase’’ resembling CIMF. Interestingly,
polycythemia and reticulocytosis were efficiently resurrected in
secondary mice by transplantation of BM and/or spleen cells from
primary JAK2 V617F recipients, and this was equally true for
Figure 4. Constitutive activation of signaling pathways by JAK2 V617F. (A–B): Western blot analysis of primary myeloerythroid cell extracts from
control (normal) mice and recipients of JAK2 WT- and JAK2 V617F-transduced BM. (A) Activated JAK2 (anti-pY1007/10008, top panel) and total JAK2
(middle panel) blots. Note that JAK2 V617F is modestly overexpressed and constitutively active. Anti-actin immunoblot demonstrating equivalent
protein loading is at the bottom. (B) Constitutive activation of Stat5, Gab2, and ERK, with overexpression of Bcl-XL in spleen cells from JAK2 V617F
recipients. Primary myeloerythroid cell extracts from mice in (A) were immunoblotted with the indicated antibodies against total or phosphorylated
Stat5, Gab2, ERK, and against Bcl-X. (C) Oligo- to polyclonal MPD in recipients of JAK2 V617F-transduced BM. Genomic DNA from spleens of individual
JAK2 V617F recipients sacrificed at the indicated times post-transplant were analyzed with a radioactive GFP probe that detects a distinct band from
each proviral integration event. For comparison, DNAs from control Ba/F3 cell lines each containing a single provirus (Con1 and Con2) and spleen
DNA from a representative mouse with BCR-ABL-induced CML-like MPD are included at left, along with DNA size markers in kb.
doi:10.1371/journal.pone.0000018.g004
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well as the later, myelofibrotic phase (Figure 5C). These results
suggest that JAK2 V617F expression induces myelofibrosis, but
the resulting impairment of erythropoiesis is due to a defect of the
hematopoietic microenvironment, rather than a deficiency of
malignant hematopoietic stem cells.
JAK2 V617F-induced polycythemia is independent
of Src kinases
This model of JAK2 V617F-induced polycythemia can be used to
investigate signaling pathways critical for disease pathogenesis.
Epo stimulation activates Src family kinases including Lyn [28],
while a Src kinase inhibitor impaired the Epo-independent
differentiation of erythroid progenitors from PV patients [12].
To investigate the role of Src kinases in the polycythemia induced
by JAK2 V617F, we employed donor mice lacking Lyn, Hck, and
Fgr, the three principal Src kinases in myeloerythroid progenitor
cells [22,29], as BM donors for transduction with JAK2 V617F.
These mice have normal baseline hematopoiesis, but defective
erythropoietic responses to stress [30]. Interestingly, recipients of
Lyn
2/2Hck
2/2Fgr
2/2 BM transduced with JAK2 V617F de-
veloped polycythemia and reticulocytosis that tended to be greater
than recipients of JAK2 V617F-transduced WT donor BM
(Figure 6A–6C), although this did not reach statistical significance.
The results demonstrate that these particular Src kinases are not
required for polycythemia induced by JAK2 V617F, and might
even play a negative role in JAK2 V617F signaling. There is
a possibility that one or more of the other six vertebrate Src family
kinases might compensate for lack of these three, particularly Fyn,
Yes, and c-Src, which are expressed in myeloid cells. However,
there was no overexpression of Fyn, Yes, or c-Src in myeloery-
throid cells from polycythemic recipients of JAK2 V617F-trans-
duced Lyn
2/2Hck
2/2Fgr
2/2 BM, and little or no detectable
activation of these Src kinases, as assessed by antibody recognizing
the phosphorylated activation loop tyrosine in Src (Figure 6D).
This suggests that compensation by other Src family members is
unlikely to play a role in polycythemia induced by JAK2 V617F in
these mutant cells.
JAK2 V617F-induced polycythemia responds to
kinase inhibitor therapy
We treated cohorts of polycythemic JAK2 V617F recipient mice
for a 2-week period with small molecule tyrosine kinase inhibitors,
including imatinib and the dual ABL/Src inhibitor dasatinib
(BMS-354825). Imatinib therapy can reduce the hematocrit in
some human PV patients, but has minimal effects on the level of
JAK2 V617F [31]. Relative to vehicle-treated controls, imatinib-
treated mice demonstrated significant decreases in hematocrit and
reticulocyte counts, while the corresponding responses to dasatinib
Figure 5. Evolution of JAK2 V617F-induced polycythemia to ‘‘spent’’
phase with myelofibrosis. (A) Box-style plots of hematocrit (red squares,
left axis) and reticulocyte counts (blue triangles, right axis) in a cohort
(n=12) of Balb/c recipients of syngeneic JAK2 V617F-transduced BM,
followed for over eight months after transplantation. Similar data were
observed for a B6 cohort (data not shown). (B) Increasing fibrosis
(demonstrated by reticulin staining) in spleen (left panels) and BM (right
panels) of representative JAK2 V617F recipients at about 3 months
(middle panels) and 7 months (bottom panels) after transplantation.
Note the marked increase in reticulin staining at 7 months in the JAK2
V617F recipients, but not in recipients of JAK2 WT-transduced BM (top
panels). (C): Efficient transfer of the PV-like MPD by transplantation of
BM from primary mice sacrificed either in the early, polycythemic phase
r
(left, n=3, sacrificed 72–167 days post-transplant) or the late,
myelofibrotic phase (right, n=2, sacrificed 208 days post-transplant),
to lethally irradiated syngeneic secondary recipients (n=6 for early
phase and n=4 for late phase). The graphs depict mean hematocrit
(black, left axis), reticulocyte count (white, right axis) and peripheral
blood leukocyte count (grey, right axis) of the donors at the time of
sacrifice, and of the recipients at day 30–70 post-transplant. For
transplants performed in the late phase of the disease, the hematocrit
and reticulocyte counts of recipients were significantly higher than of
the donors (P=0.0407 and P=0.0337, respectively, unpaired t-test),
while there was no significant difference between donors and
recipients transplanted in the early phase.
doi:10.1371/journal.pone.0000018.g005
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(Figure 7A). Imatinib therapy had no effect on hematocrit in
normal mice, and neither drug decreased the percentage of
circulating GFP
+ leukocytes (data not shown). These results
suggest that imatinib impairs JAK2 V617F-induced erythropoiesis
through inhibition of a target other than ABL or c-Kit, and
confirm that Src kinases may not be good targets for therapy in
PV. There are no JAK2 inhibitors in clinical use, but the
isoquinolinone compound JAK inhibitor I [15,32] and the
tyrphostin AG-490 [33] both inhibited the proliferation of Ba/
F3 cells expressing JAK2 V617F with an IC50 of 0.3 and 3.5 mM,
respectively (Figure 7B). AG-490 is not orally bioavailable, and
parenteral administration is complicated by its short half-life and
low solubility [33]. Nonetheless, continuous parenteral adminis-
tration of AG-490 to polycythemic mice over a 2-week period
caused a modest but significant decrease in hematocrit with a more
pronounced drop in reticulocytes (Figure 7C), suggesting that
chronic treatment with a JAK2 inhibitor would have therapeutic
benefit in PV.
DISCUSSION
The JAK2 V617F mutation has been recently identified in most
patients with PV, ET, and CIMF [13–16,34]. While the initial
frequency of the JAK2 V617F mutation reported in PV patients
varied from 65–90%, upon the application of more sensitive
sequencing methods, the mutation is detected in nearly every
patient meeting rigorous clinical criteria for PV [35]. The mutant
kinase has constitutive activity in cell lines [13,15], and can
transform IL-3 dependent hematopoietic cells such as Ba/F3 to
cytokine independence [13,15,16]. This transformation activity
may depend upon co-expression of a single-chain type I cytokine
receptor, such as Epo receptor, G-CSF receptor, or thrombopoie-
tin receptor [36]. In the initial report, retroviral expression of
JAK2 V617F in murine BM induced erythrocytosis in trans-
planted recipient mice [13], but the syndrome was not
characterized further.
Here, we have demonstrated that JAK2 V617F induces the
complete spectrum of the clinicopathological features of human
PV in mice, including polycythemia due to overproduction of
erythrocytes, increased red cell mass, low plasma Epo levels, and
presence of EEC in BM and spleen. Others have recently reported
similar findings [37,38]. Studies of familial PV have shown that the
JAK2 V617F mutation is acquired somatically [39,40], but have
suggested that mutation in another gene may precede the JAK2
mutation in PV. However, the facts that polycythemia induced in
mice by JAK2 V617F is polyclonal and manifested immediately
following engraftment argue that JAK2 V617F is both necessary
and sufficient for this phenotype. Increased expression of JAK2
Figure 6. Polycythemia induced by JAK2 V617F is independent of Src kinases. (A–C): Hematocrit (A), blood hemoglobin (B), and reticulocyte counts
(C) from normal (–) B6 mice (green), B6 recipients of B6 WT BM transduced with retrovirus expressing murine JAK2 WT (blue) or JAK2 V617F (red), and
B6 Lyn
2/2Hck
2/2Fgr
2/2 BM transduced with retrovirus expressing JAK2 V617F (orange). The difference between recipients of JAK2 V617F-transduced
Lyn
2/2Hck
2/2Fgr
2/2 BM and recipients of JAK2 WT-transduced WT BM was significant (unpaired t-tests) for hematocrit (P=0.0009), hemoglobin
(P=0.0007), and reticulocytes (P=0.0068), while the corresponding differences between recipients of JAK2 V617F-transduced BM from WT and Lyn
2/
2Hck
2/2Fgr
2/2 donors were not significant. (D) Western blot analysis of extracts of primary myeloerythroid cells from individual normal (lanes 1–3)
B6 mice, recipients of WT BM transduced with JAK2 WT retrovirus (lanes 4–5), recipients of WT BM transduced with JAK2 V617F retrovirus (lanes 6–9),
and recipients of Lyn
2/2Hck
2/2Fgr
2/2 BM transduced with JAK2 V617F retrovirus (lanes 10–14). The membrane was immunoblotted with antibody
recognizing the phosphorylated activation loop tyrosine (Y146 homolog) of c-Src, Lyn, Hck, Fyn, Lck, and Yes (top panel), and subsequently blotted
with antibody recognizing total c-Src, Fyn, Yes, and Fgr (bottom panel).
doi:10.1371/journal.pone.0000018.g006
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severity of the phenotype in PV [41], perhaps because the mutant
and WT JAK2 kinases compete for Epo receptor binding [13]. In
our model, robust polycythemia is induced by modest over-
expression of JAK2 V617F in BM with two normal JAK2 genes,
but further studies will be necessary to determine whether the
phenotype is influenced by levels of normal JAK2. Taken together,
these results establish JAK2 V617F as the direct cause of PV.
In contrast to the polycythemia, the effect of JAK2 V617F on
the leukocyte and platelet counts was more variable. JAK2 V617F
induced striking leukocytosis and neutrophilia in Balb/c mice, but
leukocytosis was much milder in B6 recipients. This finding
suggests that genetic differences between the two inbred strains
modify the leukocyte response to the mutant JAK2 kinase.
Somewhat surprisingly, there was no effect of JAK2 V617F on
the platelet count in either strain, despite the detection of proviral
gene expression (GFP) in CD41
+ cells from spleen and BM, and in
megakaryocytes purified from short-term in vitro cultures. This
suggests that JAK2 V617F does not directly induce an increase in
platelets, and that additional mutations or factors are necessary to
explain the thrombocytosis in ET patients with JAK2 V617F. This
is consistent with clinical studies demonstrating that the allelic
Figure 7. Polycythemia and reticulocytosis induced by JAK2 V617F responds to kinase inhibitor therapy. (A) Hematocrit (left panel) and reticulocyte
counts (right panel) of cohorts of mice treated with twice daily oral gavage with 100 mg/kg imatinib (n=3), 10 mg/kg dasatinib (n=4), or vehicle
(n=2), determined before initiation of therapy (white bars, ‘‘pre’’) or after 2 weeks of treatment (black bars, ‘‘post’’). The hematocrit and reticulocyte
count were significantly decreased in response to imatinib therapy (P=0.0267 and P=0.0053, respectively, unpaired t-test), while imatinib had no
effect on these parameters in normal mice (data not shown). (B) Inhibition of Ba/F3 parental cells grown in IL-3 (green squares) or Ba/F3 cells
expressing BCR-ABL (magenta triangles) or JAK2 V617F (red circles) grown without IL-3 by JAK Inhibitor I (left) or AG-490 (right). Note that both JAK
Inhibitor I and AG-490 inhibit IL-3-dependent proliferation of parental Ba/F3 cells, but only AG-490 inhibits the growth of BCR-ABL-expressing cells, as
previously reported [48]. (C) Hematocrit (left panel) and reticulocyte counts (right panel) of mice treated with continuous parenteral administration of
300 mg/day AG-490 (n=3) or vehicle (n=2), determined before initiation of therapy (white bars), or after 2 weeks of treatment (black bars). The
hematocrit and reticulocyte count were significantly decreased in response to AG-490 therapy (P=0.0134 and P=0.0374, respectively, unpaired t-
test). There was no significant effect of AG-490 on the hematocrit or reticulocyte count of recipients of JAK2 WT-transduced BM (data not shown).
doi:10.1371/journal.pone.0000018.g007
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hematopoiesis in many ET patients [42], and that ET patients
with the JAK2 V617F mutation tend to have PV-like features [43].
Despite the lack of effect on platelet number, JAK2 V617F
expression caused profound abnormalities of megakaryocyte
maturation and platelet function, manifested by small megakar-
yocytes, abnormal mitoses during proplatelet formation, and
a markedly prolonged tail bleeding time. These findings imply that
JAK2 V617F might be the direct cause of the hemostatic
abnormalities and mucosal bleeding frequently encountered in
PV patients. We did not observe any obvious thrombotic events in
our cohorts of polycythemic mice despite the significant elevation
in hematocrit, and further studies will be necessary to determine if
recipients of JAK2 V617F-transduced BM have abnormalities of
coagulation.
The polycythemia induced by JAK2 V617F was sustained for
several months, but eventually hematocrit and reticulocyte counts
returned to normal levels in both strains by 8 months after
transplantation. This was accompanied by prominent fibrosis in
both BM and spleen of these recipients. This process bears
a striking resemblance to the ‘‘spent’’ phase of PV, a condition
resembling CIMF. CIMF patients with the JAK2 V617F mutation
are clinically distinct from those lacking JAK2 mutation, and have
a worse overall prognosis [44]. Our findings suggest that some or
all CIMF patients with JAK2 V617F might actually represent PV
patients that progressed to myelofibrosis prior to diagnosis. It is not
clear whether the defective hematopoiesis in spent phase PV and
CIMF is due to a deficiency of hematopoietic stem cells, or to
a defective hematopoietic microenvironment. The fact that
polycythemia can be efficiently transplanted to secondary
recipients from mice with myelofibrosis argues that the problem
is with the soil, not the seed [45].
This model system of human PV should be valuable for
investigating the signaling pathways required for disease patho-
genesis, and for testing the response to novel therapies, particularly
drugs directed against specific molecular targets. In this report, we
investigated the role of Src family kinases in the pathogenesis of
JAK2 V617F-induced polycythemia. Although Src kinases are
activated by JAK2 in erythroid cells upon Epo stimulation [28]
and a Src inhibitor impaired Epo-independent maturation of PV
erythroid progenitors [13], we demonstrated that polycythemia
induced by JAK2 V617F was independent of Lyn, Hck, and Fgr,
the three principal Src family kinases expressed in myeloerythroid
cells. In complementary studies where diseased mice were treated
with dasatinib, a potent inhibitor of both ABL and Src kinases,
there was minimal response of polycythemia and reticulocytosis to
a regimen that is very effective for treatment of mice inoculated
with BCR-ABL-expressing cells [27]. These studies suggest that
other Src family kinases are not compensating for deficiency of
Lyn, Hck, and Fgr, and argue that therapy directed at Src kinases
will be ineffective in PV patients. By contrast, imatinib therapy did
cause a significant decrease in hematocrit and reticulocyte counts
in JAK2 V617F recipients, and similar responses have been
reported in PV patients [31]. The fact that imatinib was more
effective than dasatinib indicates that a target other than ABL or c-
Kit [46] mediates these responses. By analogy to CML, if PV is
caused directly by JAK2 V617F, then the disease should be
exquisitely sensitive to small molecule inhibitors of JAK2. There
are no inhibitors of JAK kinases in current clinical use, and
existing preclinical JAK2 inhibitors are compromised by lack of
oral bioavailability and short in vivo half-life. Nevertheless,
continuous parenteral delivery of the tyrphostin JAK2 inhibitor
AG-490 to polycythemic mice caused a modest but significant
drop in hematocrit, with a more profound decrease in reticulocyte
count. These results provide proof-of-principle that more chronic
administration of a potent, orally delivered JAK2 inhibitor should
have therapeutic effects on the polycythemia, and perhaps the
myelofibrosis and hemostatic abnormalities, suffered by MPD
patients carrying the JAK2 V617F mutation. Further studies using
this model should clarify the molecular pathogenesis of JAK2
V617F-associated MPD, and allow preclinical testing of novel
therapies for these diseases.
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